Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Marie Robin"'
Autor:
Hélène Labussière-Wallet, Stephanie Nguyen-Quoc, Amandine Luc, Thomas Remen, Jacques-Olivier Bay, Edouard Forcade, Rémi Dulery, Marie-Thérèse Rubio, Célestine Simand, Micha Srour, Maud d'Aveni, Ambroise Marçais, Sabine Furst, Arnaud Campidelli, Patrice Ceballos, Etienne Daguindau, Marie Robin, Pascal Turlure
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, In press, ⟨10.1016/j.clml.2021.07.027⟩
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, In press, ⟨10.1016/j.clml.2021.07.027⟩
International audience; BackgroundAllogeneic hematopoietic stem-cell transplantation (allo-HSCT) remains the best curative option for high-risk myelodysplastic syndrome . We retrospectively compared patient outcomes after allo-HSCT according to the i
Autor:
Marie Robin, Sara Villar
Publikováno v:
Hemato, Vol 2, Iss 34, Pp 545-555 (2021)
Myelodysplastic syndromes are clonal disorders with morphological dysplasia, a variable degree of cytopenia and a risk of transformation to acute myeloid leukemia. Prognosis is very variable and is defined by blast count, cytopenia, cytogenetics and
Autor:
Marie Robin, Dominique Valla, P. Bourrier, Pierre-Edouard Debureaux, Morgane De Boutiny, Régis Peffault de Latour, Pierre-Emmanuel Rautou, Aurélien Sutra Del Galy, Gérard Socié, Simona Pagliuca, Aurélie Plessier, David Michonneau, Anne-Marie Zagdanski, Aliénor Xhaard, Pedro Henrique Prata, Flore Sicre de Fontbrune
Publikováno v:
Haematologica
Significant morbidity and mortality have been associated with liver complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Causes and consequences of these hepato-biliary complications are various and might be life-threat
Autor:
Stephanie Nguyen-Quoc, Hélène Salvator, Catherine Paillard, Michael Loschi, Jacques-Olivier Bay, Marie Robin, Yves Beguin, Marie-Thérèse Rubio, Ana Berceanu, Marie-Laure Chabi, Constance Xhaard, Aliénor Xhaard, Patrice Ceballos, Bénédicte Bruno, Maud D'Aveni, Jean-Hugues Dalle, Xavier Poiré, Tereza Coman, Karin Bilger, Yves Chalandon
Publikováno v:
British journal of haematology, Vol. 192, No 5 (2021) pp. e121-e124
British Journal of Haematology
British Journal of Haematology, Wiley, 2021, 192 (5), pp.e121-e124. ⟨10.1111/bjh.17260⟩
British journal of haematology, Vol. 192, no.5, p. e121-e124 (2021)
British Journal of Haematology
British Journal of Haematology, Wiley, 2021, 192 (5), pp.e121-e124. ⟨10.1111/bjh.17260⟩
British journal of haematology, Vol. 192, no.5, p. e121-e124 (2021)
International audience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68d2aa0eab6239124abb4dcda267e613
https://archive-ouverte.unige.ch/unige:158639
https://archive-ouverte.unige.ch/unige:158639
Autor:
Nico Gagelmann, Michael Heuser, Christina Rautenberg, Victoria Panagiota, Heiko Becker, Dietrich W. Beelen, Marie Robin, Jürgen Finke, Yong Park, Michael Koldehoff, Friedrich Stölzel, Thomas Luft, Maarten Corsten, Nicolaus Kröger, Uwe Platzbecker, Olivier Nibourel, Rachel B. Salit, Aleksandar Radujkovic, Anita Badbaran, Guido Kobbe, Rashit Bogdanov, Bart L. Scott, Maximilian Christopeit
Publikováno v:
Blood Advances, 5, 1760-1769
Blood Adv
Blood Advances, 5, 6, pp. 1760-1769
Blood Adv
Blood Advances, 5, 6, pp. 1760-1769
The inclusion of mutation status improved risk stratification for newly diagnosed patients with chronic myelomonocytic leukemia (CMML). Stem cell transplantation is a potentially curative treatment option, and patient selection is critical because of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce521953c246c17c69bac6ae1486fa0e
https://www.ncbi.nlm.nih.gov/pubmed/33755092
https://www.ncbi.nlm.nih.gov/pubmed/33755092
Autor:
Ibrahim Yakoub-Agha, Dirk-Jan Eikema, Silvia Montoto, Hildegard Greinix, Arnon Nagler, Mohamad Mohty, Marie Robin, Yves Chalandon, Stephen D. Robinson, Christian Chabannon, Nicolaus Kröger, Liesbeth C. de Wreede, Francesco Lanza, Stefan Schönland, Malgorzata Mikulska, Zinaida Peric, Olaf Penack, Linda Koster, Annalisa Ruggeri, Grzegorz W. Basak, Jan Styczyński
Publikováno v:
Haematologica, 107(5), 1054-1063. FERRATA STORTI FOUNDATION
Haematologica, Vol. 107, No 5 (2022) pp. 1054-1063
Haematologica, Vol. 107, No 5 (2022) pp. 1054-1063
Acute graft-versus-host disease (aGvHD) remains a major threat to successful outcome following allogeneic hematopoietic cell transplantation though advances in prophylaxis and supportive care have been made. The aim of this study is to test whether t
Autor:
Victoria Panagiota, Marie Robin, Christine Wolschke, Michael Heuser, Nicolaus Kroeger, Bart L. Scott, Felicitas Thol, Nico Gagelmann, Dietrich W. Beelen, Markus Ditschkowski, Rachel B. Salit, Anita Badbaran, Bruno Cassinat
Publikováno v:
Blood. 138:314-314
Background Circulating peripheral blasts ≥1% have long been considered an unfavorable feature for patients with primary myelofibrosis. Recent findings (Masarova et al. Cancer 2020) suggested more differentiated impact of blasts on outcome. However,
Autor:
Marie Robin, Claudio G. Brunstein, Aleksandr Lazaryan, Margaret L. MacMillan, Gérard Socié, Flore Sicre de Fontbrune, Todd E. DeFor, Daniel J. Weisdorf, Mukta Arora, Rohtesh S. Mehta, Aliénor Xhaard, Régis Peffault de Latour, Bruce R. Blazar, Shernan G. Holtan, Nelli Bejanyan
Publikováno v:
Haematologica. 101:764-772
We previously reported that bone marrow grafts from matched sibling donors resulted in best graft-versus-host disease-free, relapse-free survival at 1-year post allogeneic hematopoietic cell transplantation. However, pediatric patients comprised the
Autor:
Marie Robin, Raphael Itzykson
Publikováno v:
Best Practice & Research Clinical Haematology
Best Practice & Research Clinical Haematology, 2020, 33, pp.101138-. ⟨10.1016/j.beha.2019.101138⟩
Best Practice & Research Clinical Haematology, 2020, 33, pp.101138-. ⟨10.1016/j.beha.2019.101138⟩
Chronic Myelomonocytic Leukemias are frequently diagnosed in older adults. Their prognosis is heterogeneous, but several prognostic factors can identify patients with an expected survival of a few years only, including among younger patients eligible
Autor:
Dragana Milojkovic, Dietrich W. Beelen, Marie Robin, Victoria Potter, Fabio Ciceri, Sonja Martin, Donald Bunjes, Donal P. McLornan, Yves Beguin, Linda Koster, Ibrahim Yakoub-Agha, Simona Iacobelli, Yves Chalandon, Ernst Holler, Nicolaus Kröger, Jakob Passweg, Bruno Lioure, Aleksandar Radujkovic, Tomasz Czerw, Patrick Hayden, Anne Lippinkhof-Kozijn, Martin Bornhäuser, Vittoria Malpassuti, Gerald Wulf, Jan-Erik Johansson, Henrik Sengeloev, Juan Carlos Hernandez Boluda
Publikováno v:
Blood. 134:3335-3335
Introduction Myeloproliferative Neoplasm (MPN) unclassifiable (MPN-U), is a heterogeneous disease that presents with an MPN-type clinical/ histological phenotype yet fails to meet diagnostic criteria for other MPN entities. Incidence is Methods This